Transcriptomic analysis of edited human hematopoietic stem/progenitor cells

ABSTRACT: We have developed a therapeutic strategy for beta-hemoglobinopathies aimed at reactivating fetal hemoglobin expression in red blood cells derived from human hematopoietic stem/progenitor cells edited with CRISPR/Cas9 nucleases, cytidine or adenine base editors targeting the fetal gamma-globin promoters. Here, we report the transcriptomic changes occurring in human hematopoietic stem/progenitor cells (obtained from healthy donors) 48 h after transfection with CRISPR/Cas9 nucleases, cytidine or adenine base editors.

ORGANISM(S): Homo sapiens

PROVIDER: GSE191135 | GEO | 2022/09/06

REPOSITORIES: GEO